Denmark Pharmaceuticals

Novo Nordisk A/S (NOVO-B)

Track

Track

Novo Nordisk A/S experienced significant insider selling activity during February 2026, primarily involving executive leadership. Key officers, including the CFO and CSO, divested shares early that month. As these transactions occurred over three months ago, no assessment regarding current market valuation or recent performance trends is provided.
Ticker: NOVO-B Exchange: CPH
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Upgrade for signal details

Upgrade to see score, net flow, insiders and context.

Upgrade to see full signal details →

Insider trades have triggered activity signals for Novo Nordisk A/S. Upgrade to see score, net flow, insiders and the full signal context.

Open in Activity Signals screener →
Top insiders
Trades
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
2.9
Karsten Munk Knudsen Executive Vice President, Chief Financial Officer (CFO) Officer
Transaction date
Sale
Price
40.00
Quantity 28,623
Value DKK1,736,522
2.9
Karsten Munk Knudsen Executive Vice President, Chief Financial Officer (CFO) Officer
Transaction date
Sale
Price
258.37
Quantity 40,249
Value DKK4,862,026
3.0
Martin Holst Lange Executive Vice President, R&D and Chief Scientific Officer (CSO) Officer
Transaction date
Sale
Price
467.93
Quantity 86,554
Value DKK1,566,311
2.9
Emil Kongshøj Larsen Executive Vice President, International Operations Officer
Transaction date
Sale
Price
304.72
Quantity 3,645
Value DKK1,110,721
2.8
David Moore Executive Vice President, US Operations Officer
Transaction date
Sale
Price
304.72
Quantity 6,845
Value DKK2,085,839
1.0
Stephan Engels Member of the Board of Directors Executive Director
Transaction date
Purchase
Price
312.50
Quantity 6,450
Value DKK2,015,625
2.8
David Moore Executive Vice President, US Operations Officer
Transaction date
Sale
Price
297.95
Quantity 8,160
Value DKK2,431,302
2.8
David Moore Executive Vice President, US Operations Officer
Transaction date
Purchase
Price
0.00
Quantity 18,634
Value DKK0
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2026-02-11 2026-02-10 S Sale
2.9
Karsten Munk Knudsen

Executive Vice President, Chief Financial Officer (CFO)

Officer
28,623
40.00
DKK1,736,522 		28,623 40.00 DKK1,736,522
2026-02-11 2026-02-10 S Sale
2.9
Karsten Munk Knudsen

Executive Vice President, Chief Financial Officer (CFO)

Officer
40,249
258.37
DKK4,862,026 		40,249 258.37 DKK4,862,026
2026-02-10 2026-02-09 S Sale
3.0
Martin Holst Lange

Executive Vice President, R&D and Chief Scientific Officer (CSO)

Officer
86,554
467.93
DKK1,566,311 		86,554 467.93 DKK1,566,311
2026-02-05 2026-02-04 S Sale
2.9
Emil Kongshøj Larsen

Executive Vice President, International Operations

Officer
3,645
304.72
DKK1,110,721 		3,645 304.72 DKK1,110,721
2026-02-05 2026-02-04 S Sale
2.8
David Moore

Executive Vice President, US Operations

Officer
6,845
304.72
DKK2,085,839 		6,845 304.72 DKK2,085,839
2025-11-17 2025-11-17 B Purchase
1.0
Stephan Engels

Member of the Board of Directors

Executive Director
6,450
312.50
DKK2,015,625 		6,450 312.50 DKK2,015,625
2025-11-11 2025-11-10 S Sale
2.8
David Moore

Executive Vice President, US Operations

Officer
8,160
297.95
DKK2,431,302 		8,160 297.95 DKK2,431,302
2025-11-11 2025-11-10 B Purchase
2.8
David Moore

Executive Vice President, US Operations

Officer
18,634
0.00
DKK0 		18,634 0.00 DKK0
Explore more

More insider trading research around Novo Nordisk A/S

More insider trades in Denmark
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Pharmaceuticals companies with insider activity
Insider trading in Europe
Insider trades in Europe Stoxx 600